Rilonacept in Diabetes Mellitus Type 1: Safety Study

Inclusion Criteria: * Within 5 years of diagnosis of type 1 diabetes * Between the ages of 16 to 45 years * Have at least one diabetes-related autoantibody present * Have mean C-peptide level \> 0.2 nmol/L on a mixed meal tolerance test * Be taking insulin * Complete written informed consent Exclusion Criteria: * Taking inhaled or oral steroids (for example Advair, Orapred) * Have an active infection * Have serologic evidence of HIV, Hepatitis C, Hepatitis C, or tuberculosis * Have ongoing use of medications known to affect glucose tolerance * Have a live vaccine 90 days prior to, or during this study * Taking any other experimental medication within the past 28 days * Have prior treatment with rilonacept * Have any complicating medical issues or abnormal clinical laboratory blood counts or results that interfere with study conduct; history of malignancies * Pregnant or lactating females * Males and females unwilling to use an acceptable method of contraception for the duration of the study